Central Nervous System Infections in Denmark
DASGIB
Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark
1 other identifier
observational
1,900
1 country
8
Brief Summary
The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\>17 years of age) patients with community-acquired CNS infections diagnosed and/or treated at departments of infectious diseases in Denmark since 1st of January 2015.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2015
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 12, 2018
CompletedFirst Posted
Study publicly available on registry
February 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
May 16, 2024
May 1, 2024
15 years
January 12, 2018
May 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence
Incidence of CNS infections in the adult population (\>17 years of age) in Denmark.
One year
Secondary Outcomes (7)
Glasgow Outcome Scale score
One month after end of treatment
Glasgow Outcome Scale score for viral meningitis
30 days
Glasgow Outcome Scale score for bacterial meningitis
30 days
Glasgow Outcome Scale score for encephalitis
30 days
Glasgow Outcome Scale score for neurosyphilis
2 weeks
- +2 more secondary outcomes
Interventions
Prospective observational registration of clinical characteristics and outcome
Eligibility Criteria
All patients above 17 years of age are prospectively included in the DASGIB cohort by the principal investigator at each site if they have a clinical presentation suggestive of CNS infection (e.g. any combination of neck stiffness, fever, headache or altered mental status) and either (i) Positive CSF culture or positive bacterial/viral DNA-based analysis for (community-acquired) pathogens in the CSF or (ii) a positive blood culture and CSF leukocytes \>10/mL or (iii) CSF leukocytes \> 10/mL without any alternative diagnoses more likely to explain the patients' conditions. Exceptions apply for brain abscess, neurosyphilis and neuroborreliosis and exact definitions of included CNS infections are provided below. We exclude patients with hospital-acquired CNS infections as defined by the Centers for Disease Control and Prevention (Garner et al, Am J Infect Control, 1988), or an implanted neurosurgical device.
You may qualify if:
- \- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)
- and
- Cerebrospinal fluid leukocytes\>10 cells/ml
- Patients with viral meningitis with undetermined pathogen have to have:
- CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
- In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
- and
- Proven bacterial aetiology (CSF or blood culture/DNA based technology or antigen tests)
- Patients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:
- \- CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
- In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
You may not qualify if:
- \- We exclude cases of proven or suspected autoimmune encephalitis.
- \- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)
- and
- \- Proven microbiological aetiology by culture/DNA-based technology from pus from brain abscess or blood or CSF
- \- Aspiration of pus from the brain abscess
- \- Response to antimicrobial treatment
- \- Tumour ruled out
- \- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.
- \- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)
- and
- \- CSF pleocytosis\>10 leukocytes/mL
- and
- \- Positive intrathecal B.burgdorferi antibody production index.
- and either
- \- Positive syphilis serology in serum combined with CSF leukocytes\>10/mL
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
Department of Infectious Diseases, Aalborg University Hospital
Aalborg, 9000, Denmark
Department of Infectious Diseases, Aarhus University Hospital Skejby
Aarhus, 8000, Denmark
Department of Infectious Diseases, Rigshospitalet
Copenhagen, 2100, Denmark
Herlev-Gentofte Hospital
Copenhagen, Denmark
Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital Hillerød
Hillerød, 3400, Denmark
Department of Infectious Diseases, Hvidovre Hospital
Hvidovre, 2650, Denmark
Department of Infectious Diseases, Odense University Hospital
Odense, 5100, Denmark
Department of Pulmonary and Infectious Diseases, Sjællands University Hospital Roskilde
Roskilde, 4000, Denmark
Biospecimen
Blood and CSF samples are stored whenever available
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Henrik Nielsen, Professor
Aalborg University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
January 12, 2018
First Posted
February 1, 2018
Study Start
January 1, 2015
Primary Completion (Estimated)
January 1, 2030
Study Completion (Estimated)
January 1, 2030
Last Updated
May 16, 2024
Record last verified: 2024-05